Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients.
The authors evaluated the pharmacokinetics of cefoperazone and sulbactam in 9 liver transplant patients. Cefoperazone and sulbactam were administered as an intravenous infusion over 30 minutes every 12 hours for six doses, and multiple blood samples were collected immediately after the first dose (administered during the surgery) and after the last dose. The concentrations of cefoperazone and sulbactam in serum and, when possible, in urine and bile collected over one dosing interval were measured by high-pressure liquid chromatography. The concentration of cefaperazone ranged from 436 to 4118 microg/ml, and sulbactam ranged from 3.3 to 8.7 microg/ml in the bile samples. The intraoperative clearance of cefoperazone (0.53+/-0.18 ml/min/kg) was significantly higher than the postoperative clearance (0.21+/-0.23 ml/min/kg). The half-life of cefaperazone, although not statistically significantly different, was prolonged in all patients during the postoperative period. The clearance of sulbactam (1.51+/-0.51 ml/min/kg) was lower than what is reported in patients with normal renal function but was comparable to what has been reported in patients with renal impairment and in critically ill patients. There were no significant differences in any of the pharmacokinetic parameters of sulbactam during and after surgery. The pharmacokinetic parameters of cefoperazone and sulbactam were significantly altered in liver transplant patients compared to what has been reported in normal subjects but were similar to what has been reported in patients with liver and renal impairment. There was a significant impairment in the biliary excretion of cefoperazone during the postoperative period in liver transplant patients. Although the percentage of the dose of cefoperazone excreted in the bile was drastically reduced, the biliary concentrations were generally high and above the MIC for most organisms. Given that both renal and hepatic elimination of cefoperazone is decreased, leading to a lower clearance and longer half-life in liver transplant patients, lower doses (1-2 g per day) of cefoperazone may be sufficient in liver transplant patients during the immediate postoperative period.
Muder
Robert R
RR
Department of Medicine, VA Medical Center, Pittsburgh, PA, USA.
Agarwala
Sangeeta
S
Mirani
Aja
A
Gayowski
Timothy
T
Venkataramanan
Raman
R
D000328:Adult; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics*; D001646:Bile / Q000378:metabolism; D002438:Cefoperazone / Q000493:pharmacokinetics*; D006801:Humans; D007668:Kidney / Q000378:metabolism; D016031:Liver Transplantation; D008657:Metabolic Clearance Rate; D013407:Sulbactam / Q000493:pharmacokinetics*
D000900:Anti-Bacterial Agents; D002438:Cefoperazone; D013407:Sulbactam